<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34638814</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>26</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1422-0067</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>22</Volume>
            <Issue>19</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Sep</Month>
              <Day>28</Day>
            </PubDate>
          </JournalIssue>
          <Title>International journal of molecular sciences</Title>
          <ISOAbbreviation>Int J Mol Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The Ephb2 Receptor Uses Homotypic, Head-to-Tail Interactions within Its Ectodomain as an Autoinhibitory Control Mechanism.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">10473</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms221910473</ELocationID>
        <Abstract>
          <AbstractText>The Eph receptor tyrosine kinases and their ephrin ligands direct axon pathfinding and neuronal cell migration, as well as mediate many other cell-cell communication events. Their dysfunctional signaling has been shown to lead to various diseases, including cancer. The Ephs and ephrins both localize to the plasma membrane and, upon cell-cell contact, form extensive signaling assemblies at the contact sites. The Ephs and the ephrins are divided into A and B subclasses based on their sequence conservation and affinities for each other. The molecular details of Eph-ephrin recognition have been previously revealed and it has been documented that ephrin binding induces higher-order Eph assemblies, which are essential for full biological activity, via multiple, distinct Eph-Eph interfaces. One Eph-Eph interface type is characterized by a homotypic, head-to-tail interaction between the ligand-binding and the fibronectin domains of two adjacent Eph molecules. While the previous Eph ectodomain structural studies were focused on A class receptors, we now report the crystal structure of the full ectodomain of EphB2, revealing distinct and unique head-to-tail receptor-receptor interactions. The EphB2 structure and structure-based mutagenesis document that EphB2 uses the head-to-tail interactions as a novel autoinhibitory control mechanism for regulating downstream signaling and that these interactions can be modulated by posttranslational modifications.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Yan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH 43210, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Structural Biology Program, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Robev</LastName>
            <ForeName>Dorothea</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Structural Biology Program, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Saha</LastName>
            <ForeName>Nayanendu</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Structural Biology Program, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Bingcheng</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Rammelkamp Center for Research, MetroHealth Medical Center, 2500 MetroHealth Drive, Cleveland, OH 44109, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dalva</LastName>
            <ForeName>Matthew B</ForeName>
            <Initials>MB</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neuroscience and Jefferson Center for Synaptic Biology, Thomas Jefferson University, 233 South 10th Street, Bluemle Life Sciences Building, Room 324, Philadelphia, PA 19107, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Kai</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH 43210, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Structural Biology Program, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Himanen</LastName>
            <ForeName>Juha P</ForeName>
            <Initials>JP</Initials>
            <Identifier Source="ORCID">0000-0003-4449-1369</Identifier>
            <AffiliationInfo>
              <Affiliation>Structural Biology Program, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nikolov</LastName>
            <ForeName>Dimitar B</ForeName>
            <Initials>DB</Initials>
            <AffiliationInfo>
              <Affiliation>Structural Biology Program, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 CA250067</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 DA022727</GrantID>
            <Acronym>DA</Acronym>
            <Agency>NIDA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P30 CA008748</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>09</Month>
          <Day>28</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Int J Mol Sci</MedlineTA>
        <NlmUniqueID>101092791</NlmUniqueID>
        <ISSNLinking>1422-0067</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="C586311">Ephb2 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D036183">Receptor, EphB2</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000072417" MajorTopicYN="N">Protein Domains</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D036183" MajorTopicYN="N">Receptor, EphB2</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Eph receptors</Keyword>
        <Keyword MajorTopicYN="N">X-ray crystallography</Keyword>
        <Keyword MajorTopicYN="N">fibronectin type III domain</Keyword>
        <Keyword MajorTopicYN="N">kinase activation</Keyword>
        <Keyword MajorTopicYN="N">ligand-binding domain</Keyword>
        <Keyword MajorTopicYN="N">protein–protein interfaces</Keyword>
        <Keyword MajorTopicYN="N">receptor clusters</Keyword>
        <Keyword MajorTopicYN="N">receptor tyrosine kinases (RTKs)</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>13</Day>
          <Hour>1</Hour>
          <Minute>3</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34638814</ArticleId>
        <ArticleId IdType="pmc">PMC8508685</ArticleId>
        <ArticleId IdType="doi">10.3390/ijms221910473</ArticleId>
        <ArticleId IdType="pii">ijms221910473</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Boyd A.W., Ward L.D., Wicks I.P., Simpson R.J., Salvaris E., Wilks A., Welch K., Loudovaris M., Rockman S., Busmanis I., et al.  Isolation and characterization of a novel re-ceptor-type protein tyrosine kinase (hek) from a human pre-B cell line. J. Biol. Chem. 1992;267:3262–3267. doi: 10.1016/S0021-9258(19)50725-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0021-9258(19)50725-6</ArticleId>
            <ArticleId IdType="pubmed">1737782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gale N.W., Holland S.J., Valenzuela D.M., Flenniken A., Pan L., Ryan T.E., Henkemeyer M., Strebhardt K., Hirai H., Wilkinson D., et al.  Eph Receptors and Ligands Comprise Two Major Specificity Subclasses and Are Reciprocally Compartmentalized during Embryogenesis. Neuron. 1996;17:9–19. doi: 10.1016/S0896-6273(00)80276-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0896-6273(00)80276-7</ArticleId>
            <ArticleId IdType="pubmed">8755474</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Himanen J.-P., Nikolov D.B. Eph signaling: A structural view. Trends Neurosci. 2003;26:46–51. doi: 10.1016/S0166-2236(02)00005-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0166-2236(02)00005-X</ArticleId>
            <ArticleId IdType="pubmed">12495863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cowan C.A., Henkemeyer M. The SH2/SH3 adaptor Grb4 transduces B-ephrin reverse signals. Nat. Cell Biol. 2001;413:174–179. doi: 10.1038/35093123.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/35093123</ArticleId>
            <ArticleId IdType="pubmed">11557983</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Egea J., Klein R. Bidirectional Eph–ephrin signaling during axon guidance. Trends Cell Biol. 2007;17:230–238. doi: 10.1016/j.tcb.2007.03.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tcb.2007.03.004</ArticleId>
            <ArticleId IdType="pubmed">17420126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pasquale E.B. Eph–ephrin promiscuity is now crystal clear. Nat. Neurosci. 2004;7:417–418. doi: 10.1038/nn0504-417.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nn0504-417</ArticleId>
            <ArticleId IdType="pubmed">15114347</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilkinson D.G. Multiple roles of eph receptors and ephrins in neural development. Nat. Rev. Neurosci. 2001;2:155–164. doi: 10.1038/35058515.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/35058515</ArticleId>
            <ArticleId IdType="pubmed">11256076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pasquale E.B. Eph receptor signalling casts a wide net on cell behaviour. Nat. Rev. Mol. Cell. Biol. 2005;6:462–475. doi: 10.1038/nrm1662.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm1662</ArticleId>
            <ArticleId IdType="pubmed">15928710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pasquale E.B. Eph receptors and ephrins in cancer: Bidirectional signalling and beyond. Nat. Rev. Cancer. 2010;10:165–180. doi: 10.1038/nrc2806.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc2806</ArticleId>
            <ArticleId IdType="pmc">PMC2921274</ArticleId>
            <ArticleId IdType="pubmed">20179713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Janes P.W., Adikari S., Lackmann M. Eph/ephrin signalling and function in oncogenesis: Lessons from embryonic develop-ment. Curr. Cancer Drug Targets. 2008;8:473–479. doi: 10.2174/156800908785699315.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/156800908785699315</ArticleId>
            <ArticleId IdType="pubmed">18781894</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Janes P.W., Slape C.I., Farnsworth R.H., Atapattu L., Scott A.M., Vail M.E. EphA3 biology and cancer. Growth Factors. 2014;32:176–189. doi: 10.3109/08977194.2014.982276.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/08977194.2014.982276</ArticleId>
            <ArticleId IdType="pubmed">25391995</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lisabeth E.M., Falivelli G., Pasquale E.B. Eph Receptor Signaling and Ephrins. Cold Spring Harb. Perspect. Biol. 2013;5:a009159. doi: 10.1101/cshperspect.a009159.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/cshperspect.a009159</ArticleId>
            <ArticleId IdType="pmc">PMC3753714</ArticleId>
            <ArticleId IdType="pubmed">24003208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Genander M., Halford M.M., Xu N.J., Eriksson M., Yu Z., Qiu Z., Frisén J. Dissociation of EphB2 signaling pathways mediating pro-genitor cell proliferation and tumor suppression. Cell. 2009;139:679–692. doi: 10.1016/j.cell.2009.08.048.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2009.08.048</ArticleId>
            <ArticleId IdType="pmc">PMC2786256</ArticleId>
            <ArticleId IdType="pubmed">19914164</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cissé M., Halabisky B., Harris J., Devidze N., Dubal D.B., Sun B., Orr A., Lotz G., Kim D.H., Hamto P., et al.  Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nat. Cell Biol. 2010;469:47–52. doi: 10.1038/nature09635.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature09635</ArticleId>
            <ArticleId IdType="pmc">PMC3030448</ArticleId>
            <ArticleId IdType="pubmed">21113149</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Dijken I., van der Vlag M., Flores Hernandez R., Ross A. Perspectives on Treatment of Alzheimer’s Disease: A Closer Look into EphB2 Depletion. J. Neurosci. 2017;37:11296–11297. doi: 10.1523/JNEUROSCI.0214-17.2017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.0214-17.2017</ArticleId>
            <ArticleId IdType="pmc">PMC6596747</ArticleId>
            <ArticleId IdType="pubmed">29167398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lao K., Zhang R., Luan J., Zhang Y., Gou X. Therapeutic Strategies Targeting Amyloid-beta Receptors and Transporters in Alzheimer’s Disease. J. Alzheimers Dis. 2021;79:1429–1442. doi: 10.3233/JAD-200851.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3233/JAD-200851</ArticleId>
            <ArticleId IdType="pubmed">33459712</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Himanen J.-P., Saha N., Nikolov D.B. Cell–cell signaling via Eph receptors and ephrins. Curr. Opin. Cell Biol. 2007;19:534–542. doi: 10.1016/j.ceb.2007.08.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ceb.2007.08.004</ArticleId>
            <ArticleId IdType="pmc">PMC3327877</ArticleId>
            <ArticleId IdType="pubmed">17928214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Himanen J.-P., Rajashankar K.R., Lackmann M., Cowan C.A., Henkemeyer M., Nikolov D.B. Crystal structure of an Eph receptor–ephrin complex. Nat. Cell Biol. 2001;414:933–938. doi: 10.1038/414933a.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/414933a</ArticleId>
            <ArticleId IdType="pubmed">11780069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Himanen J.P., Goldgur Y., Miao H., Myshkin E., Guo H., Buck M., Nguyen M., Rajashankar K.R., Wang B., Nikolov D.B. Ligand recognition by A-class Eph receptors: Crystal structures of the EphA2 ligand-binding domain and the EphA2/ephrin-A1 complex. EMBO Rep. 2009;10:722–728. doi: 10.1038/embor.2009.91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/embor.2009.91</ArticleId>
            <ArticleId IdType="pmc">PMC2727437</ArticleId>
            <ArticleId IdType="pubmed">19525919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chrencik J.E., Brooun A., Kraus M.L., Recht M.I., Kolatkar A.R., Han G.W., Seifert J.M., Widmer H., Auer M., Kuhn P. Structural and Biophysical Characterization of the EphB4·EphrinB2 Protein-Protein Interaction and Receptor Specificity. J. Biol. Chem. 2006;281:28185–28192. doi: 10.1074/jbc.M605766200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M605766200</ArticleId>
            <ArticleId IdType="pubmed">16867992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Himanen J.P. Ectodomain structures of Eph receptors. Semin. Cell Dev. Biol. 2012;23:35–42. doi: 10.1016/j.semcdb.2011.10.025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.semcdb.2011.10.025</ArticleId>
            <ArticleId IdType="pubmed">22044883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vearing C.J., Lackmann M. Eph receptor signalling; dimerisation just isn’t enough. Growth Factors. 2005;23:67–76. doi: 10.1080/08977190500055869.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/08977190500055869</ArticleId>
            <ArticleId IdType="pubmed">16019428</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lemmon M.A., Schlessinger J., Ferguson K.M. The EGFR Family: Not So Prototypical Receptor Tyrosine Kinases. Cold Spring Harb. Perspect. Biol. 2014;6:a020768. doi: 10.1101/cshperspect.a020768.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/cshperspect.a020768</ArticleId>
            <ArticleId IdType="pmc">PMC3970421</ArticleId>
            <ArticleId IdType="pubmed">24691965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Janes P., Nievergall E., Lackmann M. Concepts and consequences of Eph receptor clustering. Semin. Cell Dev. Biol. 2012;23:43–50. doi: 10.1016/j.semcdb.2012.01.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.semcdb.2012.01.001</ArticleId>
            <ArticleId IdType="pubmed">22261642</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schaupp A., Sabet O., Dudanova I., Ponserre M., Bastiaens P., Klein R. The composition of EphB2 clusters determines the strength in the cellular repulsion response. J. Cell Biol. 2014;204:409–422. doi: 10.1083/jcb.201305037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1083/jcb.201305037</ArticleId>
            <ArticleId IdType="pmc">PMC3912530</ArticleId>
            <ArticleId IdType="pubmed">24469634</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lackmann M., Oates A.C., Dottori M., Smith F.M., Do C., Power M., Kravets L., Boyd A.W. Distinct Subdomains of the EphA3 Receptor Mediate Ligand Binding and Receptor Dimerization. J. Biol. Chem. 1998;273:20228–20237. doi: 10.1074/jbc.273.32.20228.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.273.32.20228</ArticleId>
            <ArticleId IdType="pubmed">9685371</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Himanen J.P., Yermekbayeva L., Janes P., Walker J.R., Xu K., Atapattu L., Rajashankar K.R., Mensinga A., Lackmann M., Nikolov D.B., et al.  Architecture of Eph receptor clusters. Proc. Natl. Acad. Sci. USA. 2010;107:10860–10865. doi: 10.1073/pnas.1004148107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1004148107</ArticleId>
            <ArticleId IdType="pmc">PMC2890748</ArticleId>
            <ArticleId IdType="pubmed">20505120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seiradake E., Harlos K., Sutton G., Aricescu A.R., Jones E.Y. An extracellular steric seeding mechanism for Eph-ephrin signaling platform assembly. Nat. Struct. Mol. Biol. 2010;17:398–402. doi: 10.1038/nsmb.1782.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nsmb.1782</ArticleId>
            <ArticleId IdType="pmc">PMC3672960</ArticleId>
            <ArticleId IdType="pubmed">20228801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nikolov D.B., Xu K., Himanen J.P. Eph/ephrin recognition and the role of Eph/ephrin clusters in signaling initiation. Biochim. Biophys. Acta (BBA) Proteins Proteom. 2013;1834:2160–2165. doi: 10.1016/j.bbapap.2013.04.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbapap.2013.04.020</ArticleId>
            <ArticleId IdType="pmc">PMC3777820</ArticleId>
            <ArticleId IdType="pubmed">23628727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barton W.A., Dalton A.C., Seegar T.C.M., Himanen J.P., Nikolov D.B. Tie2 and Eph Receptor Tyrosine Kinase Activation and Signaling. Cold Spring Harb. Perspect. Biol. 2014;6:a009142. doi: 10.1101/cshperspect.a009142.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/cshperspect.a009142</ArticleId>
            <ArticleId IdType="pmc">PMC3949358</ArticleId>
            <ArticleId IdType="pubmed">24478383</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lackmann M., Boyd A.W. Eph, a Protein Family Coming of Age: More Confusion, Insight, or Complexity? Sci. Signal. 2008;1:re2. doi: 10.1126/stke.115re2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/stke.115re2</ArticleId>
            <ArticleId IdType="pubmed">18413883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu K., Tzvetkova-Robev D., Xu Y., Goldgur Y., Chan Y.P., Himanen J.P., Nikolov D.B. Insights into Eph receptor tyrosine kinase activa-tion from crystal structures of the EphA4 ectodomain and its complex with ephrin-A5. Proc. Natl. Acad. Sci. USA. 2013;110:14634–14639. doi: 10.1073/pnas.1311000110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1311000110</ArticleId>
            <ArticleId IdType="pmc">PMC3767517</ArticleId>
            <ArticleId IdType="pubmed">23959867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nikolov D.B., Xu K., Himanen J.P. Homotypic receptor-receptor interactions regulating Eph signaling. Cell Adhes. Migr. 2014;8:360–365. doi: 10.4161/19336918.2014.971684.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/19336918.2014.971684</ArticleId>
            <ArticleId IdType="pmc">PMC4594565</ArticleId>
            <ArticleId IdType="pubmed">25530219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yin Y., Yamashita Y., Noda H., Okafuji T., Go M.J., Tanaka H. EphA receptor tyrosine kinases interact with co-expressed ephrin-A ligands in cis. Neurosci. Res. 2004;48:285–295. doi: 10.1016/j.neures.2003.11.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neures.2003.11.009</ArticleId>
            <ArticleId IdType="pubmed">15154674</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carvalho R.F., Beutler M., Marler K.J., Knoll B., Becker-Barroso E., Heintzmann R., Ng T., Drescher U. Silencing of EphA3 through a cis interac-tion with ephrinA5. Nat. Neurosci. 2006;9:322–330. doi: 10.1038/nn1655.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nn1655</ArticleId>
            <ArticleId IdType="pubmed">16491080</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wimmer-Kleikamp S.H., Janes P., Squire A., Bastiaens P.I., Lackmann M. Recruitment of Eph receptors into signaling clusters does not require ephrin contact. J. Cell Biol. 2004;164:661–666. doi: 10.1083/jcb.200312001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1083/jcb.200312001</ArticleId>
            <ArticleId IdType="pmc">PMC2172175</ArticleId>
            <ArticleId IdType="pubmed">14993233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Janes P.W., Griesshaber B., Atapattu L., Nievergall E., Hii L.L., Mensinga A., Lackmann M. Eph receptor function is modulated by het-erooligomerization of A and B type Eph receptors. J. Cell. Biol. 2011;195:1033–1045. doi: 10.1083/jcb.201104037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1083/jcb.201104037</ArticleId>
            <ArticleId IdType="pmc">PMC3241718</ArticleId>
            <ArticleId IdType="pubmed">22144690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Noren N.K., Yang N., Silldorff M., Mutyala R., Pasquale E.B. Ephrin-independent regulation of cell substrate adhesion by the EphB4 receptor. Biochem. J. 2009;422:433–442. doi: 10.1042/BJ20090014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1042/BJ20090014</ArticleId>
            <ArticleId IdType="pmc">PMC2866036</ArticleId>
            <ArticleId IdType="pubmed">19552627</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mason E.O., Goldgur Y., Robev D., Freywald A., Nikolov D.B., Himanen J.P. Structure of the EphB6 receptor ectodomain. PLoS ONE. 2021;16:e0247335.  doi: 10.1371/journal.pone.0247335.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0247335</ArticleId>
            <ArticleId IdType="pmc">PMC7997048</ArticleId>
            <ArticleId IdType="pubmed">33770085</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao J., Aksoy B.A., Dogrusoz U., Dresdner G., Gross B., Sumer S.O., Sun Y., Jacobsen A., Sinha R., Larsson E., et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal. Sci. Signal. 2013;6:pl1. doi: 10.1126/scisignal.2004088.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scisignal.2004088</ArticleId>
            <ArticleId IdType="pmc">PMC4160307</ArticleId>
            <ArticleId IdType="pubmed">23550210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Himanen J.-P., Chumley M.J., Lackmann M., Li C., Barton W.A., Jeffrey P.D., Vearing C., Geleick D., Feldheim D.A., Boyd A.W., et al.  Repelling class discrimination: Ephrin-A5 binds to and activates EphB2 receptor signaling. Nat. Neurosci. 2004;7:501–509. doi: 10.1038/nn1237.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nn1237</ArticleId>
            <ArticleId IdType="pubmed">15107857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou Q., Qiu H. The Mechanistic Impact of N-Glycosylation on Stability, Pharmacokinetics, and Immunogenicity of Therapeutic Proteins. J. Pharm. Sci. 2019;108:1366–1377. doi: 10.1016/j.xphs.2018.11.029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.xphs.2018.11.029</ArticleId>
            <ArticleId IdType="pubmed">30471292</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anthony R.M., Ravetch J.V. A Novel Role for the IgG Fc Glycan: The Anti-inflammatory Activity of Sialylated IgG Fcs. J. Clin. Immunol. 2010;30:9–14. doi: 10.1007/s10875-010-9405-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10875-010-9405-6</ArticleId>
            <ArticleId IdType="pubmed">20480216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferluga S., Hantgan R., Goldgur Y., Himanen J.P., Nikolov D.B., Debinski W. Biological and Structural Characterization of Glycosylation on Ephrin-A1, a Preferred Ligand for EphA2 Receptor Tyrosine Kinase. J. Biol. Chem. 2013;288:18448–18457. doi: 10.1074/jbc.M113.464008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M113.464008</ArticleId>
            <ArticleId IdType="pmc">PMC3689987</ArticleId>
            <ArticleId IdType="pubmed">23661698</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanamura K., Washburn H.R., Sheffler-Collins S.I., Xia N.L., Henderson N., Tillu D.V., Hassler S., Spellman D.S., Zhang G., Neubert T.A., et al.  Extracellular phosphorylation of a receptor tyrosine kinase controls synaptic localization of NMDA receptors and regulates pathological pain. PLoS Biol. 2017;15:e2002457.  doi: 10.1371/journal.pbio.2002457.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pbio.2002457</ArticleId>
            <ArticleId IdType="pmc">PMC5515392</ArticleId>
            <ArticleId IdType="pubmed">28719605</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goldgur Y., Susi P., Karelehto E., Sanmark H., Lamminmaki U., Oricchio E., Himanen J.P. Generation and characterization of a sin-gle-chain anti-EphA2 antibody. Growth Factors. 2014;32:214–222. doi: 10.3109/08977194.2014.983225.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/08977194.2014.983225</ArticleId>
            <ArticleId IdType="pmc">PMC4335687</ArticleId>
            <ArticleId IdType="pubmed">25494541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Charmsaz S., Al-Ejeh F., Yeadon T.M., Miller K.J., Smith F.M., Stringer B., Moore A., Lee F.-T., Cooper L.T., Stylianou C., et al.  EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia. Leukemia. 2017;31:1779–1787. doi: 10.1038/leu.2016.371.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/leu.2016.371</ArticleId>
            <ArticleId IdType="pubmed">27922598</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mao W., Luis E., Ross S., Silva J., Tan C., Crowley C., Chui C., Franz G., Senter P., Koeppen H., et al.  EphB2 as a therapeutic antibody drug target for the treatment of colorectal cancer. Cancer Res. 2004;64:781–788. doi: 10.1158/0008-5472.CAN-03-1047.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-03-1047</ArticleId>
            <ArticleId IdType="pubmed">14871799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lamminmäki U., Nikolov D., Himanen J. Eph Receptors as Drug Targets: Single-Chain Antibodies and Beyond. Curr. Drug Targets. 2015;16:1021–1030. doi: 10.2174/1389450116666150531154619.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1389450116666150531154619</ArticleId>
            <ArticleId IdType="pubmed">26028047</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Otwinowski Z., Minor W.  Processing of X-ray diffraction data collected in oscillation mode. In: Carter C.W. Jr., editor. Methods in Enzymology: Mac-Romolecular Crystallography Part A. Academic Press; Cambridge, MA, USA: 1997. pp. 307–326.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27799103</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McCoy A.J., Grosse-Kunstleve R.W., Adams P.D., Winn M.D., Storoni L.C., Read R.J. Phaser crystallographic software. J. Appl. Crystallogr. 2007;40:658–674. doi: 10.1107/S0021889807021206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1107/S0021889807021206</ArticleId>
            <ArticleId IdType="pmc">PMC2483472</ArticleId>
            <ArticleId IdType="pubmed">19461840</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adams P.D., Afonine P.V., Bunkóczi G., Chen V.B., Davis I.W., Echols N., Headd J.J., Hung L.-W., Kapral G.J., Grosse-Kunstleve R.W., et al.  PHENIX: A comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. Sect. D Biol. Crystallogr. 2019;66:213–221. doi: 10.1107/S0907444909052925.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1107/S0907444909052925</ArticleId>
            <ArticleId IdType="pmc">PMC2815670</ArticleId>
            <ArticleId IdType="pubmed">20124702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Emsley P., Cowtan K. Coot: Model-building tools for molecular graphics. Acta Crystallogr. Sect. D Biol. Crystallogr. 2004;60:2126–2132. doi: 10.1107/S0907444904019158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1107/S0907444904019158</ArticleId>
            <ArticleId IdType="pubmed">15572765</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
